Crohn

1

1

2

1/- 4 2

Crohn

( )

,

: 20-30 60-70

-

Bowel rest

Anti-TNF

Infliximab

Adalimumab

Certolizumab pegol

Anti-integrin 4 Vedolizumab

Natalizumab

Infliximab

EMA approval: 1999

mAb IgG1 -

:

Crohn

:

, ,

:

, , , , ,

Adalimumab

EMA approval: 2003

mAb IgG1

TNF

:

Crohn

:

infliximab

:

, , , -, , ,

Certolizumab pegol

FDA approval: 2008

- (Kawalek et al, 2013)

The role of selected integrinsin lymphocyte migration

Natalizumab

FDA approval: 2008

-4

PML (JC virus) EMA

MS

Vedolizumab

EMA approval: 2014

mAb IgG1 -47

:

Crohn, anti-TNF ( )

:

,

:

, ,

CD + UC = IBD

anti-TNF anti-integrin 4 nti-TNF: infliximab, adalimumab

Anti-integrin 4: vedolizumab